新里程收盘上涨1.86%，滚动市盈率66.17倍，总市值74.18亿元

Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line including drugs and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 796 million yuan, a year-on-year decrease of 16.49% [1] - The net profit for the same period was 25.65 million yuan, reflecting a year-on-year decline of 9.35% [1] - The sales gross margin stood at 27.96% [1] Market Position - The company's stock closed at 2.19 yuan, with a rise of 1.86%, resulting in a rolling price-to-earnings (PE) ratio of 66.17 times [1] - The total market capitalization of the company is 7.418 billion yuan [1] - In comparison to the medical services industry, which has an average PE of 43.60 times and a median of 46.78 times, New Mile ranks 34th in terms of PE ratio [2] Shareholding Structure - As of the first quarter of 2025, seven institutions hold shares in New Mile, including five other entities, one brokerage, and one fund, with a total holding of 1.3909269 billion shares valued at 3.436 billion yuan [1]